Accessibility StatementSkip Navigation BENSALEM, Pa., Sept. 30, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Quantum Corporation ("Quantum" or the "Company") (NASDAQ:Â QMCO). SOURCE Law Offices of Howard G. Smith WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN QUANTUM CORPORATION (QMCO), CONTACT THE LAW OFFICES OF HOWARD G. ...

PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) --  Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the “Company”) following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the “Class Period”). Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class ...

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 30, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against V.F. Corporation (NYSE: VFC) ("VFC" or the "Company") on behalf of investors who purchased or acquired shares during the period from October 30, 2023 through May 20, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired VFC securities during the Class Period may, no later than November 12, 2025, seek to ...

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Charter Communications, Inc. (NASDAQ: CHTR) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Charter, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/charter-communications-inc-class-action-lawsuit. Investors have until October 14, 2025, to ask ...

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into CarMax, Inc. (NYSE: KMX) for potential violations of the federal securities laws. If you invested in CarMax, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/carmax-inc-class-action. Why Is CarMax being Investigated?CarMax sells used cars. During the relevant period, the Company touted the strong and sustainable demand for its cars, ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Fortinet, Inc. (“Fortinet” or the “Company”) (NASDAQ:FTNT) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost. If you suffered a loss on your Fortinet investments, you have until November 21, 2025 to request lead plaintiff appointment. Fol ...

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Snap Inc. (NYSE: SNAP) securities between April 29, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), have until Monday, October 20, 2025 to seek appointment as lead plaintiff of the Snap class action lawsuit. Captioned Abdul-Hameed v. Snap Inc., No. 25-cv-07844 (C.D. Cal.), the Snap class action lawsuit charges Snap as well as certain of Snap’s top execu ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-submission-form/?id=169623&from=3 CLASS ...

Core Viewpoint - The Lantheus Holdings, Inc. class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly concerning its key product, Pylarify, which is used in prostate cancer diagnosis and treatment [3][4][5]. Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases globally, with Pylarify being a significant product in its portfolio [2]. Allegations of Misrepresentation - The lawsuit claims that Lantheus's executives created a false impression of the company's revenue projections and growth while downplaying risks from competition and market dynamics [3]. - It is alleged that Lantheus's optimistic sales growth reports for Pylarify did not align with actual market conditions, leading to a lack of accurate understanding of pricing and competitive dynamics [3]. Financial Performance and Stock Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales, attributing it to a "temporal competitive disruption," and subsequently lowered its full-year growth projections from low-single-digit to mid-single-digit growth to flat-to-low single-digit growth [4]. - Following this announcement, Lantheus's stock price fell by more than 23% [4]. - On August 6, 2025, the company announced further disappointing results, with Pylarify sales down 8.3% year-over-year, leading to a nearly 29% drop in stock price after slashing fiscal year 2025 growth projections [5]. Legal Process for Lead Plaintiff - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Lantheus securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [6].

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of Nutex Health Inc. (NASDAQ: NUTX) (“Nutex” or the “Company”). The lawsuit seeks to recover losses on behalf of investors who purchased the Company’s securities between August 8, 2024 and August 14, 2025, inclusive (the “Class Period”). If you purchased Nutex securities and suffered losses, you have until October 21, 2025, to seek appointment as lead plaintiff. Inves ...